Optimizing Biologic Agents in Ulcerative Colitis and Crohn’s Disease

被引：14
作者：
O’Toole A. [1 ]
Moss A.C. [1 ]
机构：
[1] Beth Israel Deaconess Medical Center & Harvard Medical School, 330 Brookline Avenue, Boston, 02215, MA
来源：
Current Gastroenterology Reports | 2015年 / 17卷 / 8期
关键词：
Adalimumab; Antibodies; Biologics; Crohn’s disease; Inflammatory bowel disease; Infliximab; Therapeutic drug monitoring; Trough levels; Ulcerative colitis;
D O I：
10.1007/s11894-015-0453-1
中图分类号：
学科分类号：
摘要：
The goals of therapy in inflammatory bowel disease (IBD) are the induction and maintenance of clinical and biological remission. Mucosal healing is desirable to prevent complications and reduce the need for surgery, hospitalizations, and steroid exposure. Therapeutic monoclonal antibodies (biologic agents) have revolutionized the treatment of IBD. The initial magnitude of the clinical/biologic response to these agents has been associated with a number of underlying phenotypic features in the recipient. In addition, the durability of the initial response often declines over time. This can occur due to low drug serum drug levels, anti-drug antibodies, and a shift to alternative inflammatory pathways. This review discusses strategies that may optimize the initial response to biologics and sustain this to improve patient outcomes. © 2015, Springer Science+Business Media New York.
引用
收藏
页数：8
相关论文
共 73 条
[1]  
Plevy S.E., Targan S.R., Anti-tumor necrosis factor-alpha therapy in Crohn’s disease: a magic bullet finally hits its mark, Inflamm Bowel Dis, 2, 2, pp. 158-159, (1996)
[2]  
Costa J., Et al., Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis, Inflamm Bowel Dis, 19, 10, pp. 2098-2110, (2013)
[3]  
Chen J.S., Et al., Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis, Arthritis Care Res (Hoboken), 66, 3, pp. 464-472, (2014)
[4]  
Kestens C., Et al., Adalimumab and infliximab are equally effective for Crohn’s disease in patients not previously treated with anti-tumor necrosis factor-alpha agents, Clin Gastroenterol Hepatol, 11, 7, pp. 826-831, (2013)
[5]  
Osterman M.T., Et al., Comparative effectiveness of infliximab and adalimumab for Crohn’s disease, Clin Gastroenterol Hepatol, 12, 5, (2014)
[6]  
Patil S.A., Et al., Comparative effectiveness of anti-TNF agents for Crohn’s disease in a tertiary referral IBD practice, Dig Dis Sci, 58, 1, pp. 209-215, (2013)
[7]  
Sandborn W.J., Et al., Natalizumab induction and maintenance therapy for Crohn’s disease, N Engl J Med, 353, 18, pp. 1912-1925, (2005)
[8]  
Feagan B.G., Et al., Treatment of active Crohn’s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin, Clin Gastroenterol Hepatol, 6, 12, pp. 1370-1377, (2008)
[9]  
Sandborn W.J., Et al., Vedolizumab as induction and maintenance therapy for Crohn’s disease, N Engl J Med, 369, 8, pp. 711-721, (2013)
[10]  
Van Assche G., Et al., Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease, N Engl J Med, 353, 4, pp. 362-368, (2005)
12345678